: COVID-19 Drug Veklury (Remdesivir) Update

Date: July 5, 2022Attention: All ProvidersEffective Date: April 25, 2022Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated with the COVID-19 event.  TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event. Call to action: Texas Children’s Health Plan (TCHP) would like to inform providers that effective April 25, 2022, Veklury (J0248) is a covered benefit for Medicaid and CHIP clients 28 days or older when used in an outpatient setting. Previously, Veklury (remdesivir lyophilized injection) was approved for patients 12 years or older. How this impacts providers: On April 25, 2022, the U.S. Food and Drug Administration (FDA) expanded the use of Veklury (remdesivir lyophilized injection) for patients in the outpatient setting. Veklury is indicated for patients meeting all the following:

• age 28 days or older
• weighing at least 3kg
• having mild to moderate COVID-19
• are at high risk for progression to severe COVID-19, including hospitalization or death

Additional Information: Veklury Package InsertFDA Veklury Approval Letter Next steps for providers: Prescribers should share this communication with their staff. If you have any questions, please email Provider Network Management at: providerrelations@texaschildrens.org.For access to all provider alerts,log into: www.thecheckup.org or www.texaschildrenshealthplan.org/for-providers